NCT06714370View on ClinicalTrials.gov

Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: a Nationwide Study

Not yet recruitingOBSERVATIONAL
Enrollment

35

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Primary Central Nervous System Lymphoma (PCNSL)
Sponsors
All Listed Sponsors
lead

Ono Pharmaceutical Co. Ltd

INDUSTRY

NCT06714370 - Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: a Nationwide Study | Biotech Hunter | Biotech Hunter